Uses a PET scan to track heart protein deposits in transthyretin amyloidosis
Tests a PET scan using 18F-fluoride in adults with heart disease.
Plain-language title generated from the registry record
Registry title: Quantitative-imaging in Cardiac Transthyretin Amyloidosis
Key facts
- Where
- Groningen, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cardiac amyloidosis (ATTR or AL) or hypertrophic cardiomyopathy, to test a new heart scan called 18F-fluoride PET.
- Age
- Over 40 years for ATTR or AL cardiac amyloidosis; over 30 years for hypertrophic cardiomyopathy.
- Sex
- All sexes can join.
- Disease stage
- ATTR cardiac amyloidosis, AL amyloidosis or hypertrophic cardiomyopathy, diagnosed by expert consensus or European Society of Cardiology guidelines.
Main reasons for not taking part
- Pregnant, breastfeeding or of child-bearing potential women
- Kidney dysfunction (eGFR ≤30 mL/min/1.73m2)
- NYHA Class IV heart failure
- Atrial fibrillation with poor rate control
- Contraindications to MR, gadolinium contrast allergy, or contraindications to tafamidis
Read by machine on 12 November 2026.
Where in Netherlands
- University Medical Centre GroningenGroningen, NetherlandsContact: Riemer HJ Slart, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Edinburgh
- Trial code
- NCT05776212
- Record updated
- 26 June 2026
- Original description
Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM.Read full original descriptionShow less
Quantitative-imaging in Cardiac Transthyretin Amyloidosis
Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM.
Hypotheses:
1. A delayed imaging protocol and state-of-the-art PET motion correction will optimise 18F-fluoride imaging in ATTR-CM and provide a clear threshold in myocardial TBR values for the diagnosis of ATTR-CM. 2. Optimised 18F-fluoride PET will provide a quantitative marker of the ATTR-CM burden that will allow disease progression and treatment response to be tracked. 3. Myocardial 18F-fluoride TBR values will reduce in patients responding to tafamidis treatment and increase in non-responders and patients not receiving therapy
Inclusion: Completion of informed consent; Age > 40 years for patients with ATTR or AL cardiac amyloidosis and age >30 years for patients with HCM; ATTR cardiac amyloid according to Expert Consensus Recommendations; AL amyloidosis according to Expert Consensus Recommendations; Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines.
Exclusion: Previous history of contrast allergy of adverse reactions (gadolinium); Contraindications to tafamidis therapy; NYHA Class IV heart failure; Renal dysfunction (eGFR ≤30 mL/min/1.73m2); Inability or unwilling to give informed consent; Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial; Patients with atrial fibrillation and poor rate control; Contraindications to MR.